Overview

Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer

Status:
RECRUITING
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24
Phase:
PHASE3
Details
Lead Sponsor:
Il-Yang Pharm. Co., Ltd.
Treatments:
ilaprazole
Lansoprazole